dc.contributor.author | Hiyoshi, H | |
dc.contributor.author | Abdelhady, S | |
dc.contributor.author | Segerström, L | |
dc.contributor.author | Sveinbjørnsson, Baldur | |
dc.contributor.author | Nuriya, M | |
dc.contributor.author | Lundgren, T | |
dc.contributor.author | Desfrere, L | |
dc.contributor.author | Miyakawa, A | |
dc.contributor.author | Yasui, M. | |
dc.contributor.author | Kogner, P | |
dc.contributor.author | Johnsen, JI | |
dc.contributor.author | Andang, M | |
dc.contributor.author | Uhlén, P | |
dc.date.accessioned | 2013-03-13T10:32:54Z | |
dc.date.available | 2013-03-13T10:32:54Z | |
dc.date.issued | 2012 | |
dc.description.abstract | Cellular quiescence is a state of reversible proliferation arrest that is induced by anti-mitogenic signals. The endogenous cardiac glycoside ouabain is a specific ligand of the ubiquitous sodium pump, Na,K-ATPase, also known to regulate cell growth through unknown signalling pathways.
To investigate the role of ouabain/Na,K-ATPase in uncontrolled neuroblastoma growth we used xenografts, flow cytometry, immunostaining, comet assay, real-time PCR, and electrophysiology after various treatment strategies.
The ouabain/Na,K-ATPase complex induced quiescence in malignant neuroblastoma. Tumour growth was reduced by >50% when neuroblastoma cells were xenografted into immune-deficient mice that were fed with ouabain. Ouabain-induced S-G2 phase arrest, activated the DNA-damage response (DDR) pathway marker γH2AX, increased the cell cycle regulator p21Waf1/Cip1 and upregulated the quiescence-specific transcription factor hairy and enhancer of split1 (HES1), causing neuroblastoma cells to ultimately enter G0. Cells re-entered the cell cycle and resumed proliferation, without showing DNA damage, when ouabain was removed.
Conclusion:
These findings demonstrate a novel action of ouabain/Na,K-ATPase as a regulator of quiescence in neuroblastoma, suggesting that ouabain can be used in chemotherapies to suppress tumour growth and/or arrest cells to increase the therapeutic index in combination therapies. | en |
dc.identifier.citation | British Journal of Cancer 106(2012) nr. 11 s. 1807-1815 | en |
dc.identifier.cristinID | FRIDAID 948085 | |
dc.identifier.doi | http://dx.doi.org/10.1038/bjc.2012.159 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://hdl.handle.net/10037/4981 | |
dc.identifier.urn | URN:NBN:no-uit_munin_4720 | |
dc.language.iso | eng | en |
dc.publisher | Nature Publishing Group | en |
dc.rights.accessRights | openAccess | |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical molecular biology: 711 | en |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk molekylærbiologi: 711 | en |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical microbiology: 715 | en |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi: 715 | en |
dc.title | Quiescence and gamma H2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase | en |
dc.type | Journal article | en |
dc.type | Tidsskriftartikkel | en |
dc.type | Peer reviewed | en |